+38 (067) 242 82 22

+38 (067) 242 82 22

Amyotrophic lateral sclerosis

It is possible to slow down the progression of amyotrophic lateral sclerosis with cell therapy.

Safe stem cells

Stem cells will stop the disease progression!

Heading photo

The capability of GOOD CELLS

In amyotrophic lateral sclerosis (ALS), central and peripheral motoneurons are destroyed, accompanied by progressive loss of motor activity, muscle weakness, and atrophy. Usually, ALS lesions are generalized. Even in the absence of clinical manifestations, degenerative changes can be observed on electroneuromyography. Patients with ALS develop paralysis of the upper and lower extremities, also speech, swallowing, breathing, and heart rhythm disorders.
Today, we can talk about slowing down the ALS progression, not cure. Methods of ALS treatment are still being studied quite actively. The well-known Ice Bucket Challenge, which was popular in 2014, aimed to obtain funds for the study of ALS.
The GOOD CELLS team is also studying this disease and doing everything possible to reduce its effects. As a treatment, we offer a combination of mesenchymal stem cells from adipose tissue (MSCs of adipose tissue) and neural crest-derived multipotent stem cells (NC-MSCs).
Therapeutic techniques include endolumbar, intravenous injection, and local administration of stem cells. It is important to repeat the injection every six months.

Heading photo

For whom is this treatment?

This treatment is indicated for patients over 18 y.o. with diagnosed amyotrophic lateral sclerosis.
cancer, or its history during 5 years; pregnancy; mental disorders; alcohol and drug addiction.

Heading photo

Why MSC?

Mesenchymal stem cells (MSCs) can differentiate not only into mesodermal cell lines but also into endoderm and ectoderm derivatives, including neurons and glial cells. For this reason, MSCs are widely studied as a therapeutic option for pathologies with poor results after pharmacological treatment. Such diseases include amyotrophic lateral sclerosis, which is characterized by the progressive death of motoneurons, causing motor disorders.

The full spectrum of MSCs action mechanisms has not been fully studied. Still, the results of numerous studies and our observations indicate the MSCs-mediate neurogenesis, stimulation of angiogenesis, anti-apoptotic, immunomodulatory, and anti-inflammatory effects. In addition, MSCs show the ability to go directly to the affected areas.

Thus, our proposed cell therapy can suspend the development of ALS. On average, precise results can be noted 6 months after the introduction of MSCs.

Safe stem cells

The treatment process


Consultation with a manager

Contact our managers with no obligations on your side. At this step, we gather your medical information and confirm the diagnosis. After that, we'll arrange a free online or offline consultation with a doctor.


Online/offline consultation with a doctor 

A personal consultation with a doctor is an excellent opportunity for you to find out all details of the program and get an individual prognosis. All the medical information you provide will be carefully reviewed so that you get the most effective treatment. The procedures take place in our clinical institutions in Kyiv, Ukraine. The course of the treatment is developed individually and lasts 3 days and more.



During the checkup, the doctor assesses your readiness for cell therapy. If the assessment is positive, biological materials are taken. Depending on your doctor's recommendations, you may be prescribed your own* or donor stem cells.
*If you are prescribed the treatment with your own cells, you will have an ear punch biopsy performed under anesthesia in an operating room. The procedure lasts for 15 minutes. The punch depth is up to 4 mm, and the diameter is up to 3 mm.


Preparation of the stem cell product

OWN CELLSAfter the biomaterials are collected, our team of biotechnologists will prepare a therapeutic dose of stem cells. In our laboratory, we will select stem cells from your sample, grow the required number of cells, test them, then create a stem cell product for your treatment. Usually, the production takes up to 21 days.
DONOR CELLSAccording to the doctor's prescription, the biotechnologist will select a ready-made and pre-tested sample of donor cells from our cryobank in the required quantity. In this case, cell injection can happen immediately after diagnosis and drug preparation.


Start of treatment

During the first visit, you will consult a doctor and have instrumental, clinical, and laboratory checkups. If the doctor needs to clarify the disease and its course, you may be prescribed needle electromyography or stimulation combined with a needle. If necessary, you may be offered additional MRIs.


Pharmacological therapy

Based on the results of the checkup, the doctor may prescribe the drug therapy by intravenous infusion and intramuscular injection.


Injection of the cellular product, the regeneration phase

The doctor may prescribe endolumbar injection, intravenous cell therapy, and local injection of cells. It is recommended to repeat the injection once every 6 months.


Medical assessment report and weakening of the basic treatment

You will be provided with a medical assessment report that states the diagnosis, the examination results (clinical, laboratory, and instrumental), the treatment process, and further recommendations. The doctor will examine you, select the necessary treatment, or adjust the one prescribed to you at the time of arrival at the clinic.


Keeping in touch

The results can be observed in 6 months after the treatment — you will see the improvement of the regenerative processes in the body.
Throughout the program, you will have a personal manager who will ensure the best communication between you and the clinic. After treatment, our patients are advised to maintain contact with us. We'll ask you to fill out a questionnaire in 3 and 6 months after the treatment to evaluate the progress and answer all questions.

Safe stem cells

Scientific evidence

A study by Barczewska M. et al. showed that intrathecal administration of UC-MSCs in patients with ALS prolongs overall survival almost twice compared to untreated patients (1183 days vs. 640 days, p = 0.002). The risk of death was decreased by 70% in UC-MSCs treated group vs. the paired control group. 21 out of 67 (31.3%) treated patients showed a reduced rate of ALS progression according to the ALSFRS-R scale. The outcome is better for females and in case of a positive response to the first UC-MSCs administration.
You can get acquainted with the details of the research at the following link:
Barczewska, M., Maksymowicz, S., Zdolińska-Malinowska, I. et al. Umbilical Cord Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis: an Original Study. Stem Cell Rev and Rep 16, 922–932, 2020. https://doi.org/10.1007/s12015-020-10016-7